SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as the community rallies around its strong performance within the Injective ecosystem and its potential for high gains. Bullish sentiment is fueled by the anticipation of a staked $INJ ETF, which some believe could drive further momentum for this memecoin. Community members are actively discussing its unique features, such as the burned liquidity pool, and its potential to outperform other meme coins.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

The crypto 4CHAN.X is gaining traction as community members rally around its potential, emphasizing its roots in internet culture and the long-term vision. Some investors are highlighting the coin's scarcity and encouraging others to accumulate, while dismissing negative sentiment. The community also seems to be responding to recent price volatility, reaffirming a commitment to holding.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid speculation surrounding potential inclusion in the S&P 500, with the official announcement expected soon. The community is actively discussing potential price movements based on the outcome, with some bracing for volatility regardless of the decision. Broader market sentiment and the upcoming Robinhood summit are also contributing to the heightened interest in the stock.

Krypto Cock is a meme-powered crypto project with real onchain utility. Born from the lessons of past market cycles, $COCK blends humor, culture, and technology to create a unique community-driven ecosystem.  The project is focused on: • Building lightweight mini-apps for Farcaster and other onchain platforms • Developing an engaged, growing community • Delivering consistent, high-quality content • Offering practical onchain tools and experiences • Led by a team with years of crypto and product experience  $COCK aims to make the crypto experience more fun, accessible, and connected, without sacrificing purpose or quality.

CockCardano

$COCK.X is trending as the community rallies around the launch of CockyWings LLC, a real-world food business, generating excitement for its potential revenue streams. The community emphasizes the project's focus on combining a meme-driven approach with tangible utility on the Cardano network. Many are anticipating the potential for long-term growth and real-world adoption.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending amid community debate over its valuation and future catalysts, particularly following recent earnings and raised guidance. Discussions revolve around technical analysis versus fundamental strength, with some highlighting potential for a market correction. Community members are closely watching for news of contract wins or a possible acquisition.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions around its association with political figures and recent news, including labor reports and tariff implications. Community talking points involve debates over economic policies, the Epstein files, and the company's valuation. The stock's performance is generating strong opinions and speculative commentary.

Cardano is a proof-of-stake blockchain platform designed to support decentralized applications (dApps), featuring a multi-asset ledger and smart contract functionality. Unlike many other blockchains, Cardano is built from the ground up based on original academic research, with proposed solutions undergoing peer review and presentation at international conferences before development. The platform emphasizes a research-driven and formal methods approach to design and implementation.

Cardano

Cardano is trending as the community discusses the launch of Cocky Wings, a food business and memecoin on the Cardano blockchain, generating excitement around real-world asset integration. Discussions also involve potential rate cuts and their impact on crypto markets, with some anticipating a liquidity boost for risk-on assets like Cardano. Additionally, updates on Keeta Anchors and their potential to enhance Cardano's capabilities are circulating.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics ($RNAZ) is trending due to promising Phase 1a trial results for its metastatic cancer drug, TTX-MC138, showing stable disease in some patients and no dose-limiting toxicities, sparking significant community interest. Discussions revolve around the potential for a short squeeze, warrant triggers, and speculation on whether the company will cancel its planned reverse stock split given the recent positive momentum. Investors are closely watching for further news and catalysts, hopeful for continued positive data that could drive the stock higher.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to positive analyst outlooks and strong Auvelity sales growth, although a recent market downturn is also a factor. Community discussions highlight the potential for the company to achieve profitability and speculation around upcoming FDA decisions for its Alzheimer's agitation treatment. The focus remains on the company's CNS pipeline and expansion opportunities.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo ($MLGO) is trending due to speculation around a potential short squeeze and anticipation of a significant price surge, with some traders citing its low float and previous large runs. Community members are actively discussing potential entry points, dilution concerns, and the stock's volatile history as a possible pump-and-dump scheme. The stock's movements are also being compared to other Chinese-related stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Gains 35% in 3 Months: How Should You Play the Stock?

MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mirumpharma.com/news-events/News/news-details/2025/Mirums-LIVMARLI-Now-FDA-Approved-in-Tablet-Formulation/default.aspx">announced</a> that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of its drug Livmarli for the treatment of cholestatic pruritus in patients with certain liver diseases.Livmarli is an orally administered ileal bile acid transporter inhibitor. It is used to treat cholestatic pruritus or intense itching caused by impaired bile flow in patients with rare liver diseases called Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).Mirum President Peter Radovich said that the approval for Livmarli in tablet form provides a “meaningful additional treatment option” for patients with ALGS and PFIC.He said that while younger patients can use liquid dosing, older patients can use a one-tablet-per-dose option. He added that the company has had “tremendous success” with Livmarli since launch.In 2024, Livmarli's net product <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mirumpharma.com/news-events/News/news-details/2025/Mirum-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Business-Update/default.aspx">sales</a> totaled $213.3 million, accounting for a whopping 63% of the company’s total net product sales.The tablets are expected to be available in June through Mirum Access Plus pharmacy.On Stocktwits, retail sentiment around Mirum Pharmaceuticals jumped further into the ‘bullish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:649/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_2_10_41_PM_png_a632468a1b.webp" alt="MIRM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 14, 2025 | Source: Stocktwits" width="649" height="149"><figcaption>MIRM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the shares have been forming a “good base” since last year and stand the potential of touching $60.<stembedurl>https://stocktwits.com/buddyopalosam/message/611569108</stembedurl><a href="https://stocktwits.com/symbol/MIRM">MIRM stock</a> is down by over 6% year-to-date but has gained over 64% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cara-therapeutics-announces-1-for-3-reverse-stock-split/chfCXBzRbaQ">Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

Equity

Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI (chenodiol) tablets, a bile acid, for the treatment of adults with...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

MIRM
Mirum Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIRM News

MIRM Mirum Pharmaceuticals Inc